Skip to content
Menu
Home
About Us
Life Wins
Chairman’s Profile
Board Of Directors
Team Wockhardt
Corporate Milestones
Research & Development
R&D at Wockhardt
New Drug Discovery
Pipeline / Projects
News & Events
Publications
WCK 5222
WCK 4873
WCK 4282
WCK 6777
Biologicals
News & Events
Pipeline / Projects
Publications
R&D Contact
Our Business Verticals
Our Manufacturing Units
Global Footprint
India
UK & Europe
US
Emerging Markets
Products
India Branded Business
Trademark Products
Quality
Digital Footprint
Awards & Recognitions
Investors
From Chairman’s Office
AGM Speech
Letter to Shareowners
Financials
Financials at a Glance
Annual Report
Quarterly Results
Financial Press Releases
Related Party Transactions
Subsidiary Financials
Annual Return
Corporate Governance
Policies & Codes
Committee’s of the Board
Familiarisation programs
Shareholding Pattern
Secretarial Compliance Report
Authorised KMP
Corporate Actions
Announcements / Disclosures
Shareholders Meeting/ Postal ballot
AGM Notice
Proceedings
IEPF
Unclaimed Dividend
Nodal Officer
Analyst/ Investors
Presentation
Audio / Video Recording
Transcript
Shareowner Services
FAQ
Green Initiative
Investor Contact
Stock Quotes
Credit Rating
careers
Introduction
Life@Wockhardt
L&D Initiatives
Voice of Wockhardians
The Wockhardian
Career@Wockhardt
Media
Press Release
Media Coverage
Video Coverage
Media Kit
Sustainability
Contact us
Home
/
2015-2016
/
Page 2
PDF Year:
2015-2016
Home
For Quarter-ended 31ST December, 2015
US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt
Chairman’s Letter to Shareowners Q2 FY2015 – 16
FINANCIAL RESULTS FY 2015 – 16 Q2 (JUL – SEP 2015)
FINANCIAL RESULTS FY16 Q2
For Quarter-ended Sep 30, 2015
Chairman’s Letter to Shareowners Q1 FY2015 – 16
FINANCIAL RESULTS FY 2015 – 16 Q1 (APR – JUN 2015)
FINANCIAL RESULTS FY16 Q1
Annual report 2015 – 2016
Posts navigation
Previous page
Page
1
Page
2
Page
3
Next page
